Articles from NeuroQure

NeuroQure, a pioneering leader in neurological diagnostics, announces the launch of ASD Insight, a first-of-its-kind test designed to identify autism risk as early as birth. Representing a critical step in redefining autism as a biologically measurable condition, ASD Insight provides clinicians and families with unprecedented early insight into autism risk, enabling earlier, targeted interventions during the most critical stages of neurodevelopment.

IRVINE, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- NeuroQure, a pioneering biotech startup specializing in gene therapy for neurocognitive disorders, has reached a pivotal milestone in the development of its first commercial product. The company has acquired the exclusive rights to license a patent portfolio from the UC Irvine Center for Autism Research and Translation (CART). This intellectual property, developed over 7 years with an investment of over $14 million, forms the cornerstone for the creation of precise diagnostic tools for autism spectrum disorder (ASD) and related intellectual disabilities.

IRVINE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- NeuroQure has embarked on a transformative journey aimed at revolutionizing the treatment landscape for Fragile X Syndrome and Autism Spectrum Disorder (ASD). With an unwavering commitment to addressing the monogenic origins of these conditions, NeuroQure, founded by businessman Dave Justus and renowned geneticist Dr. Jay Gargus, MD, Ph.D., is pioneering a path toward curative treatments.